CEO James C. Katzaroff of Advanced Medical Isotope Corp Interviewed by the Uptick Network Radio Show

KENNEWICK, WA – (Uptick Newswire – August 5, 2016) – Advanced Medical Isotope Corp (OTCPK: ADMD), a late stage radiation oncology focused medical device company, today announced that James C. Katzaroff, CEO and Chairman, was interviewed by Everett Jolly on the Uptick Network Stock Day Radio Show.

Mr. Katzaroff discussed the company’s medical advancements and treatments using radioimmunotherapy. He also mentions the company diving into the veterinary market with a program at Washington State University in which they are studying cancer in cats.

“What we really want to do is we believe we can save thousands of lives more economically and less barbaric than the things that are out there now,” said Katzaroff.

The podcast is currently available for streaming on various platforms, including AudioBoom (www.audioBoom.com) and iHeart Radio (www.iheartradio.com).

 

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

 

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACT:

Advanced Medical Isotope Corporation

James C. Katzaroff, CEO

1021 N Kellogg
Kennewick WA 99336
509-736-4000

Investors:
Circadian Group, IR
Tyler Troup, B. Comm
1-(866)-950-8300
info@circadian-group.com

Source: Uptick Newswire